Ecns wire

China's domestically-developed oral COVID drug to enter market in February

2022-12-29 Editor : Zhang Dongfang ECNS App Download

(ECNS) -- SIM0417, an oral COVID drug developed by China, is expected to enter the market in February 2023, according to the Jiangsu Medical Products Administration.

SIM0417 (Xiannuoxin in Chinese), co-developed by Nanjing-based Simcere Group, the Shanghai Institute of Materia Medica and the Wuhan Institute of Virology under the Chinese Academy of Sciences, is a highly active small molecule candidate COVID-19 drug that targets the 3C-like protease, a key enzyme in the replication and life cycle of coronaviruses, including SARS-CoV-2.

Preclinical animal models have demonstrated good antiviral activity and safety of SIM0417. Due to the 3CL protease's highly conserved nature, SIM0417 has a strong inhibitory effect on a variety of SARS-CoV-2 variants, including the highly infectious Delta and Omicron.

It is available for the treatment of mild and moderate COVID-19 patients and prevention of severe COVID-19 symptoms.

The drug has been granted two approvals on March 28 and May 13, 2022 by Chinese authorities to start clinical trials for its efficacy to treat COVID-19 and prevent the virus in people with a high infection risk.

The phase III clinical study of the drug has completed all enrollment of 1,208 patients in December, the Simcere Group announced on Dec. 18.


Most popular in 24h

MoreTop news


Back to top About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2022 All rights reserved.
Reproduction in whole or in part without permission is prohibited.
[网上传播视听节目许可证(0106168)] [京ICP证040655号]
[京公网安备 11010202009201号] [京ICP备05004340号-1]